全球流感疫苗市場:2023-2033
市場調查報告書
商品編碼
1371507

全球流感疫苗市場:2023-2033

Influenza Vaccines Market Report 2023-2033

出版日期: | 出版商: Visiongain Reports Ltd. | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

預計到 2033 年,全球流感疫苗市場規模將以 10.5% 的複合年增長率成長。

全球流感大流行呈上升趨勢。 預防廣泛感染最有效的方法是接種疫苗。 隨著世界人口老化,人們變得更容易感染流感,增加了對流感疫苗的需求。 已開發國家對流感的認識不斷提高、醫療保健服務的改善以及出生率的提高,導致預測期內流感疫苗的需求增加。

本報告調查了全球流感疫苗市場,提供了市場概況,分析了市場成長的各種影響因素、市場規模的趨勢和預測、各個細分市場/地區/主要國家的細分以及競爭環境。的主要公司。

目錄

第 1 章報告概述

第 2 章執行摘要

第三章市場概述

  • 主要調查結果
  • 市場動態
    • 市場驅動因素
    • 市場限制因素
    • 市場機會
  • 新冠肺炎 (COVID-19) 影響分析
  • 波特五力分析
  • PEST分析

第四章流感疫苗市場分析:依疫苗類型

  • 主要調查結果
  • 市場吸引力指數
  • 估計與預測市場規模
  • 四價
  • 三價

第 5 章流感疫苗市場分析:依最終使用者劃分

  • 主要調查結果
  • 市場吸引力指數
  • 估計與預測市場規模
  • 專科診所
  • 醫院
  • 其他

第六章流感疫苗市場分析:依地區

  • 主要調查結果
  • 估計與預測市場規模

第七章北美流感疫苗市場分析

第八章歐洲流感疫苗市場分析

第九章亞太流感疫苗市場分析

第十章拉丁美洲流感疫苗市場分析

第十一章中東及非洲流感疫苗市場分析

第十二章公司簡介

  • CSL
  • Emergent BioSolutions Inc.
  • GSK plc
  • Pfizer Inc.
  • Sanofi
  • AstraZeneca
  • SINOVAC
  • Viatris Inc.(Mylan)
  • Abbott Laboratories
  • BIKEN Co., Ltd.

第 13 章一般性評論/建議

  • Visiongain 概述
  • 對進入市場的公司的建議
Product Code: PHA1288

The global Influenza Vaccines market is projected to grow at a CAGR of 10.5% by 2033.

“The Influenza Vaccines Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

The global prevalence of influenza is on the rise. The most effective method of averting the widespread infection is through vaccination. As the global population ages, individuals become more susceptible to influenza, which increases the demand for influenza vaccines. Increasing awareness of influenza, the improvement of healthcare services, and high birth rates in developed nations will all contribute to increased demand for current and new influenza vaccines during the forecast period. As a result, the influenza vaccine sector exhibits substantial growth prospects and robust revenue generation. Vaccination is a stressful experience, especially for children; therefore, an organisation that provides a non-stressful vaccine stands to gain substantial benefits.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the influenza vaccines market evolving?
  • What is driving and restraining the influenza vaccines market?
  • How will each influenza vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each influenza vaccines submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading influenza vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the influenza vaccines projects for these leading companies?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of

influenza vaccines projects taking place now and over the next 10 years?

  • Is there a greater need for product commercialisation to further scale the influenza vaccines market?
  • Where is the influenza vaccines market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the influenza vaccines market today, and over the next 10 years:

  • Our 192-page report provides 77 tables and 116 charts/graphs exclusively to you
  • The report highlights key lucrative areas in the industry so you can target them - NOW
  • It contains in-depth analysis of global, regional and national sales and growth
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the influenza vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
  • You will find original analyses, with business outlooks and developments
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Vaccine Type

  • Quadrivalent
  • Trivalent

End-users

  • Specialty Clinics
  • Hospitals
  • Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:

North America

  • U.S
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • South-East Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Influenza Vaccines Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

  • Abbott Laboratories
  • AstraZeneca
  • BIKEN Co., Ltd.
  • CSL
  • Emergent BioSolutions Inc.
  • GSK plc
  • Pfizer Inc
  • Sanofi
  • SINOVAC
  • Viatris Inc. (Mylan)

Overall world revenue for Influenza Vaccines Market, 2023 to 2033 in terms of value the market will surpass US$6,600.0million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Influenza Vaccines Market, 2023 to 2033 report help you?

In summary, our 190+ page report provides you with the following knowledge:

  • Revenue forecasts to 2033 for Influenza Vaccines Market 2023 to 2033, with forecasts for vaccine type and end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 21 key national markets - See forecasts for the Influenza Vaccines Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the Influenza Vaccines Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Influenza Vaccines Market 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Influenza Vaccines Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Growing Elderly Population Driving Industry Growth
      • 3.2.1.2 Growing Interest in Vaccine Development
      • 3.2.1.3 High Prevalence of Infectious Diseases Anticipated to Spur Industry Growth
      • 3.2.1.4 Increase in Government Focus on Immunization Programs
      • 3.2.1.5 Paediatric Influenza Vaccines Boosting Industry Growth
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Inadequate Reimbursement Coverage Likely to Challenge Industry Growth
      • 3.2.2.2 Longer Timelines for Vaccine Development Projected to Hamper Market Growth
      • 3.2.2.3 Supply Chain Constraints
      • 3.2.2.4 Storage and Handling Challenges
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Emerging Economies
      • 3.2.3.2 Personalized Vaccination Strategies
      • 3.2.3.3 Pandemic Preparedness and Stockpiling
      • 3.2.3.4 Education and Public Awareness Campaigns
      • 3.2.3.5 Strong R&D Pipeline
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Supplier Power
    • 3.4.2 Buyer Power
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis
    • 3.5.1 Political Factors
    • 3.5.2 Economic Factors
    • 3.5.3 Social Factors
    • 3.5.4 Technological Factors

4 Influenza Vaccines Market Analysis by Vaccine Type

  • 4.1 Key Findings
  • 4.2 Vaccine Type Segment: Market Attractiveness Index
  • 4.3 Influenza Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 4.4 Quadrivalent
    • 4.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
    • 4.4.2 Market Share by Region, 2023 & 2033 (%)
  • 4.5 Trivalent
    • 4.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
    • 4.5.2 Market Share by Region, 2023 & 2033 (%)

5 Influenza Vaccines Market Analysis by End-users

  • 5.1 Key Findings
  • 5.2 End-users Segment: Market Attractiveness Index
  • 5.3 Influenza Vaccines Market Size Estimation and Forecast by End-users
  • 5.4 Specialty Clinics
    • 5.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
    • 5.4.2 Market Share by Region, 2023 & 2033 (%)
  • 5.5 Hospitals
    • 5.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
    • 5.5.2 Market Share by Region, 2023 & 2033 (%)
  • 5.6 Others
    • 5.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
    • 5.6.2 Market Share by Region, 2023 & 2033 (%)

6 Influenza Vaccines Market Analysis by Region

  • 6.1 Key Findings
  • 6.2 Regional Market Size Estimation and Forecast

7 North America Influenza Vaccines Market Analysis

  • 7.1 Key Findings
  • 7.2 North America Influenza Vaccines Market Attractiveness Index
  • 7.3 North America Influenza Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 7.4 North America Influenza Vaccines Market Size Estimation and Forecast by Country
  • 7.5 North America Influenza Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 7.6 North America Influenza Vaccines Market Size Estimation and Forecast by End-users
  • 7.7 U.S. Influenza Vaccines Market Analysis
  • 7.8 Canada Influenza Vaccines Market Analysis

8 Europe Influenza Vaccines Market Analysis

  • 8.1 Key Findings
  • 8.2 Europe Influenza Vaccines Market Attractiveness Index
  • 8.3 Europe Influenza Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 8.4 Europe Influenza Vaccines Market Size Estimation and Forecast by Country
  • 8.5 Europe Influenza Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 8.6 Europe Influenza Vaccines Market Size Estimation and Forecast by End-users
  • 8.7 Germany Influenza Vaccines Market Analysis
  • 8.8 UK Influenza Vaccines Market Analysis
  • 8.9 France Influenza Vaccines Market Analysis
  • 8.10 Italy Influenza Vaccines Market Analysis
  • 8.11 Spain Influenza Vaccines Market Analysis
  • 8.12 Russia Influenza Vaccines Market Analysis
  • 8.13 Rest of Europe Influenza Vaccines Market Analysis

9 Asia Pacific Influenza Vaccines Market Analysis

  • 9.1 Key Findings
  • 9.2 Asia Pacific Influenza Vaccines Market Attractiveness Index
  • 9.3 Asia Pacific Influenza Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 9.4 Asia Pacific Influenza Vaccines Market Size Estimation and Forecast by Country
  • 9.5 Asia Pacific Influenza Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 9.6 Asia Pacific Influenza Vaccines Market Size Estimation and Forecast by End-users
  • 9.7 Japan Influenza Vaccines Market Analysis
  • 9.8 China Influenza Vaccines Market Analysis
  • 9.9 India Influenza Vaccines Market Analysis
  • 9.10 Australia Influenza Vaccines Market Analysis
  • 9.11 South Korea Influenza Vaccines Market Analysis
  • 9.12 South-East Asia Influenza Vaccines Market Analysis
  • 9.13 Rest of Asia Pacific Influenza Vaccines Market Analysis

10 Latin America Influenza Vaccines Market Analysis

  • 10.1 Key Findings
  • 10.2 Latin America Influenza Vaccines Market Attractiveness Index
  • 10.3 Latin America Influenza Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 10.4 Latin America Influenza Vaccines Market Size Estimation and Forecast by Country
  • 10.5 Latin America Influenza Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 10.6 Latin America Influenza Vaccines Market Size Estimation and Forecast by End-users
  • 10.7 Brazil Influenza Vaccines Market Analysis
  • 10.8 Mexico Influenza Vaccines Market Analysis
  • 10.9 Rest of Latin America Influenza Vaccines Market Analysis

11 MEA Influenza Vaccines Market Analysis

  • 11.1 Key Findings
  • 11.2 MEA Influenza Vaccines Market Attractiveness Index
  • 11.3 MEA Influenza Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 11.4 MEA Influenza Vaccines Market Size Estimation and Forecast by Country
  • 11.5 MEA Influenza Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 11.6 MEA Influenza Vaccines Market Size Estimation and Forecast by End-users
  • 11.7 GCC Influenza Vaccines Market Analysis
  • 11.8 South Africa Influenza Vaccines Market Analysis
  • 11.9 Rest of MEA Influenza Vaccines Market Analysis

12 Company Profiles

  • 12.1 CSL
    • 12.1.1 Company Snapshot
    • 12.1.2 Company Overview
    • 12.1.3 Financial Analysis
      • 12.1.3.1 Net Revenue, 2015-2022
      • 12.1.3.2 R&D, 2015-2022
      • 12.1.3.3 Regional Market Shares, 2022
    • 12.1.4 Product Benchmarking
    • 12.1.5 Strategic Outlook
  • 12.2 Emergent BioSolutions Inc.
    • 12.2.1 Company Snapshot
    • 12.2.2 Company Overview
    • 12.2.3 Financial Analysis
      • 12.2.3.1 Net Revenue, 2015-2022
      • 12.2.3.2 R&D, 2015-2022
    • 12.2.4 Product Benchmarking
  • 12.3 GSK plc
    • 12.3.1 Company Snapshot
    • 12.3.2 Company Overview
    • 12.3.3 Financial Analysis
      • 12.3.3.1 Net Revenue, 2015-2022
      • 12.3.3.2 R&D, 2015-2022
      • 12.3.3.3 Regional Market Shares, 2022
    • 12.3.4 Product Benchmarking
    • 12.3.5 Strategic Outlook
  • 12.4 Pfizer Inc.
    • 12.4.1 Company Snapshot
    • 12.4.2 Company Overview
    • 12.4.3 Financial Analysis
      • 12.4.3.1 Net Revenue, 2015-2022
      • 12.4.3.2 R&D, 2015-2022
    • 12.4.4 Product Benchmarking
    • 12.4.5 Strategic Outlook
  • 12.5 Sanofi
    • 12.5.1 Company Snapshot
    • 12.5.2 Company Overview
    • 12.5.3 Financial Analysis
      • 12.5.3.1 Net Revenue, 2015-2022
      • 12.5.3.2 R&D, 2015-2022
      • 12.5.3.3 Regional Market Shares, 2022
    • 12.5.4 Product Benchmarking
    • 12.5.5 Strategic Outlook
  • 12.6 AstraZeneca
    • 12.6.1 Company Snapshot
    • 12.6.2 Company Overview
    • 12.6.3 Financial Analysis
      • 12.6.3.1 Net Revenue, 2015-2022
      • 12.6.3.2 R&D, 2015-2022
      • 12.6.3.3 Regional Market Shares, 2022
    • 12.6.4 Product Benchmarking
    • 12.6.5 Strategic Outlook
  • 12.7 SINOVAC
    • 12.7.1 Company Snapshot
    • 12.7.2 Company Overview
    • 12.7.3 Financial Analysis
      • 12.7.3.1 Net Revenue, 2015-2022
      • 12.7.3.2 R&D, 2015-2022
    • 12.7.4 Product Benchmarking
    • 12.7.5 Strategic Outlook
  • 12.8 Viatris Inc. (Mylan)
    • 12.8.1 Company Snapshot
    • 12.8.2 Company Overview
    • 12.8.3 Financial Analysis
      • 12.8.3.1 Net Revenue, 2015-2022
      • 12.8.3.2 Regional Market Shares, 2022
      • 12.8.3.3 R&D, 2015-2022
    • 12.8.4 Product Benchmarking
  • 12.9 Abbott Laboratories
    • 12.9.1 Company Snapshot
    • 12.9.2 Company Overview
    • 12.9.3 Financial Analysis
      • 12.9.3.1 Net Revenue, 2015-2022
      • 12.9.3.2 Regional Market Shares, 2022
      • 12.9.3.3 R&D, 2015-2022
    • 12.9.4 Product Benchmarking
  • 12.10 BIKEN Co., Ltd.
    • 12.10.1 Company Snapshot
    • 12.10.2 Company Overview
    • 12.10.3 Product Benchmarking
    • 12.10.4 Strategic Outlook

13 Conclusion and Recommendations

  • 13.1 Concluding Remarks from Visiongain
  • 13.2 Recommendations for Market Players

List of Tables

  • Table 1 Influenza Vaccines Market Snapshot, 2023 & 2033 (US$ million, CAGR %)
  • Table 2 Influenza Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 Influenza Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 Influenza Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
  • Table 5 Influenza Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
  • Table 6 Influenza Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 7 Quadrivalent Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 8 Trivalent Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 9 Influenza Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 10 Specialty Clinics Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 11 Hospitals Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 12 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 13 Influenza Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 14 North America Influenza Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 15 North America Influenza Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 16 North America Influenza Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 17 U.S. Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 18 Canada Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 19 Europe Influenza Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 20 Europe Influenza Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 21 Europe Influenza Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 22 Germany Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 23 UK Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 24 France Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 25 Italy Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 26 Spain Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 27 Russia Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 28 Rest of Europe Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 29 Asia Pacific Influenza Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 30 Asia Pacific Influenza Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 31 Asia Pacific Influenza Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 32 Japan Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 33 China Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 34 India Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 35 Australia Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 36 South Korea Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 37 South-East Asia Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 38 Rest of Asia Pacific Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 39 Latin America Influenza Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 40 Latin America Influenza Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 41 Latin America Influenza Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 42 Brazil Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 43 Mexico Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 44 Rest of Latin America Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 45 MEA Influenza Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 46 MEA Influenza Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 47 MEA Influenza Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 48 GCC Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 49 South Africa Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 50 Rest of MEA Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 51 CSL: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 52 CSL: Product Benchmarking
  • Table 53 CSL: Strategic Outlook
  • Table 54 Emergent BioSolutions Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 55 Emergent BioSolutions Inc.: Product Benchmarking
  • Table 56 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 57 GSK plc: Product Benchmarking
  • Table 58 GSK plc: Strategic Outlook
  • Table 59 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 60 Pfizer Inc.: Product Benchmarking
  • Table 61 Pfizer Inc.: Strategic Outlook
  • Table 62 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 63 Sanofi: Product Benchmarking
  • Table 64 Sanofi: Strategic Outlook
  • Table 65 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 66 AstraZeneca: Product Benchmarking
  • Table 67 AstraZeneca: Strategic Outlook
  • Table 68 SINOVAC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 69 SINOVAC: Product Benchmarking
  • Table 70 SINOVAC: Strategic Outlook
  • Table 71 Viatris Inc. (Mylan): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 72 Viatris Inc. (Mylan): Product Benchmarking
  • Table 73 Abbott Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 74 Abbott Laboratories: Product Benchmarking
  • Table 75 BIKEN Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 76 BIKEN Co., Ltd.: Product Benchmarking
  • Table 77 BIKEN Co., Ltd.: Strategic Outlook

List of Figures

  • Figure 1 Influenza Vaccines Market Segmentation
  • Figure 2 Influenza Vaccines Market by Vaccine Type: Market Attractiveness Index
  • Figure 3 Influenza Vaccines Market by End-users: Market Attractiveness Index
  • Figure 4 Influenza Vaccines Market Attractiveness Index by Region
  • Figure 5 Influenza Vaccines Market: Market Dynamics
  • Figure 6 Influenza Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 7 Influenza Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 8 Influenza Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 9 Influenza Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 10 Influenza Vaccines Market: Porter's Five Forces Analysis
  • Figure 11 Influenza Vaccines Market: PEST Analysis
  • Figure 12 Influenza Vaccines Market Attractiveness Index by Vaccine Type
  • Figure 13 Influenza Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 14 Influenza Vaccines Market Share Forecast by Vaccine Type, 2023, 2028, 2033 (%)
  • Figure 15 Quadrivalent Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 16 Quadrivalent Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 17 Trivalent Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 18 Trivalent Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 19 Influenza Vaccines Market Attractiveness Index by Vaccine Type
  • Figure 20 Influenza Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 21 Influenza Vaccines Market Share Forecast by End-users, 2023, 2028, 2033 (%)
  • Figure 22 Specialty Clinics Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 23 Specialty Clinics Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 24 Hospitals Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 25 Hospitals Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 26 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 27 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 28 Influenza Vaccines Market Forecast by Region 2023, 2028, 2033 (Revenue, CAGR%)
  • Figure 29 Influenza Vaccines Market Share Forecast by Region 2023, 2028, 2033 (%)
  • Figure 30 Influenza Vaccines Market by Region, 2023-2033 (US$ Mn, AGR %)
  • Figure 31 North America Influenza Vaccines Market Attractiveness Index
  • Figure 32 North America Influenza Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 33 North America Influenza Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 34 North America Influenza Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 35 North America Influenza Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 36 North America Influenza Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 37 North America Influenza Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 38 North America Influenza Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 39 U.S. Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 40 Canada Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 41 Europe Influenza Vaccines Market Attractiveness Index
  • Figure 42 Europe Influenza Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 43 Europe Influenza Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 44 Europe Influenza Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 45 Europe Influenza Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 46 Europe Influenza Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 47 Europe Influenza Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 48 Europe Influenza Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 49 Germany Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 50 UK Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 51 France Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 52 Italy Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 53 Spain Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 54 Russia Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 55 Rest of Europe Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 56 Asia Pacific Influenza Vaccines Market Attractiveness Index
  • Figure 57 Asia Pacific Influenza Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 58 Asia Pacific Influenza Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 59 Asia Pacific Influenza Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 60 Asia Pacific Influenza Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 61 Asia Pacific Influenza Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 62 Asia Pacific Influenza Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 63 Asia Pacific Influenza Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 64 Japan Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 65 China Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 66 India Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 67 Australia Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 68 South Korea Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 69 South-East Asia Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 70 Rest of Asia Pacific Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 71 Latin America Influenza Vaccines Market Attractiveness Index
  • Figure 72 Latin America Influenza Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 73 Latin America Influenza Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 74 Latin America Influenza Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 75 Latin America Influenza Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 76 Latin America Influenza Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 77 Latin America Influenza Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 78 Latin America Influenza Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 79 Brazil Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 80 Mexico Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 81 Rest of Latin America Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 82 MEA Influenza Vaccines Market Attractiveness Index
  • Figure 83 MEA Influenza Vaccines Market by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 84 MEA Influenza Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 85 MEA Influenza Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 86 MEA Influenza Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 87 MEA Influenza Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 88 MEA Influenza Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 89 MEA Influenza Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 90 GCC Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 91 South Africa Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 92 Rest of MEA Influenza Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 93 CSL: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 94 CSL: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 95 CSL: Regional Market Shares, 2022
  • Figure 96 Emergent BioSolutions Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 97 Emergent BioSolutions Inc.: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 98 GSK plc: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 99 GSK plc: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 100 GSK plc: Regional Market Shares, 2022
  • Figure 101 Pfizer Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 102 Pfizer Inc.: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 103 Sanofi: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 104 Sanofi: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 105 Sanofi: Regional Market Shares, 2022
  • Figure 106 AstraZeneca: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 107 AstraZeneca: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 108 AstraZeneca: Regional Market Shares, 2022
  • Figure 109 SINOVAC: Net Revenue, 2015-2022 (US$ Million, AGR %)
  • Figure 110 SINOVAC: R&D, 2015-2022 (US$ Million, AGR %)
  • Figure 111 Viatris Inc. (Mylan): Net Revenue, 2015-2022 (US$ million, AGR%)
  • Figure 112 Viatris Inc. (Mylan): Regional Market Shares (%), 2022
  • Figure 113 Viatris Inc. (Mylan): R&D, 2015-2022 (US$ million, AGR%)
  • Figure 114 Abbott Laboratories: Net Revenue, 2015-2022 (US$ million, AGR%)
  • Figure 115 Abbott Laboratories: Regional Market Shares (%), 2022
  • Figure 116 Abbott Laboratories: R&D, 2015-2022 (US$ million, AGR%)